Token Aggregration Rule Selection.

(DOCX)</p

Correlates of Smoking in Overall Group^*.

<p>Correlates of Smoking in Overall Group<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0153103#t003fn001" target="_blank">^*</a>.</p

Patient Characteristics^*.

<p>Patient Characteristics<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0153103#t001fn001" target="_blank">^*</a>.</p

Correlates of Smoking in HIV Patients.

Correlates of Smoking in HIV Patients.</p

Performance of NLP-based^†† Algorithm by Patient Characteristic.

<p>Performance of NLP-based<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0153103#t002fn004" target="_blank">^††</a> Algorithm by Patient Characteristic.</p

Cancer free survival curves in new glargine and NPH insulin users.

<p>Cancer free survival curves in new glargine and NPH insulin users.</p

Baseline unadjusted and propensity score weighted characteristics of new glargine and NPH insulin users.

<p>Note: Only patients with nonmissing values for all covariates are included. All variables were included in the logistic regression for propensity score.</p><p>Baseline unadjusted and propensity score weighted characteristics of new glargine and NPH insulin users.</p

Comparison of cancer incidence between new glargine and NPH users (Intent-to-Treat Analysis).

<p>CI, confidence interval; HR, hazard ratio. Note: Unadjusted HR and 95% CI were obtained from a Cox proportional hazards model adjusting for treatment only. Adjusted HR and 95% CI were obtained from a Cox proportional hazards model that adjusted for all variables listed in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0109433#pone-0109433-t001" target="_blank">table 1</a> using inverse probability of treatment weights. Patients were followed until the first occurrence of one of the following events: the patient developed cancer, death, the study ended, or one year after the patient’s last visit in the database.</p><p>Comparison of cancer incidence between new glargine and NPH users (Intent-to-Treat Analysis).</p

Association between long-acting insulin use and cancer for new users by dose category (As-Treated Analysis).

<p>Hazard ratios and their 95% CIs were obtained from Cox proportional hazards models adjusted for gender and age at the start of the dose category.</p><p>CI, confidence interval; HR, hazard ratio; IR, incidence rate per 100 person-years.</p><p>Patients were followed until the first occurrence of one of the following events: the patient switched treatments or augmented with another long-acting insulin, the patient developed cancer, death, the study ended, or one year after the patient’s last visit in the database.</p><p>Only patients with dose data for the insulin treatment that they initiated are included in this analysis.</p><p>Association between long-acting insulin use and cancer for new users by dose category (As-Treated Analysis).</p

Variables associated with age at T2D diagnosis, HbA1c at T2D diagnosis, and urine albumin-to-creatinine ratio (U_ACR) at T2D diagnosis.

*<p>Corrected P by Bonferroni method,</p>†<p>Common covariates: sex, BMI_20y, SBP, DBP, alcohol intake, smoking status, exercise habit, family history of diabetes, ΔWt, and Rate_{max_wt}.</p>‡<p>Common covariates+Age_T2D,</p>¶<p>Common covariates+Age_T2D+HbA1c_T2D+log-triglyceride/HDL-cholesterol.</p>#<p>Log-transformed value was used.</p